Latest News

Circassia Announces Publication of ToleroMune® Cat Allergy Treatment Clinical Results in Journal of Allergy and Clinical Immunology

Rapid four-dose regimen maintains significant symptom reduction one year after start of treatment

27 September 2012

Circassia Appoints Stewart Sharpe as Vice President Commercial Operations

Newly-Created Position to Lead Commercialisation Preparations for Lead Allergy Programme

18 September 2012

Circassia Appoints Dr Brett Haumann as Chief Medical Officer

11 September 2012

Circassia’s Canadian Joint Venture With McMaster University Initiates Two Clinical Studies to Explore Biomarkers of ToleroMune® Treatment Effectiveness

Studies to investigate proteomic and genetic responses to ToleroMune therapy

09 August 2012

NIH Awards $6.4 Million to Professor Mark Larché to Investigate Mechanisms of Allergy Tolerance Generated by Circassia’s ToleroMune® Treatment

07 June 2012

More recent news articles

Previous news articles

Did you know?

The average bed could be home to up to 1.5 million house dust mites